Effects of Active Video Games on Cardiometabolic Health in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials
JMIR Serious Games · 2026-10-13 · 14 · e101833-e101833
DOI: 10.2196/101833 ↗Abstract
Abstract Background Cardiometabolic risk factors emerging during childhood and adolescence may persist into adulthood and increase the risk of cardiovascular disease. Although physical activity improves cardiometabolic health, maintaining regular participation remains challenging. Active video games (AVG), which combine physical activity with video game enjoyment, may provide an engaging approach to promote physical activity participation. Objective This study aims to evaluate the effects of AVG on cardiometabolic health in children and adolescents and to explore potential moderators of these effects. Methods PubMed, Web of Science, the Cochrane Library, and Embase were searched from database inception to July 2026. Eligible randomized controlled trials (RCTs) evaluating AVG in children and adolescents aged 4‐18 years were included, with comparisons against no intervention, sedentary video games, or regular physical activity. Random-effects meta-analyses were conducted to estimate pooled effects. Subgroup analyses explored potential moderators. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool (RoB 2; Cochrane), sensitivity analyses examined robustness, and small-study effects were evaluated when feasible. Certainty of evidence was assessed using GRADE (Grading of Recommendations Assessment, Development and Evaluation). Results A total of 14 RCTs involving 942 children and adolescents were included. AVG were associated with a small but significant reduction in BMI (Hedges g =−0.23, 95% CI −0.35 to −0.10; 95% prediction interval [PI] −0.43 to −0.01; P =.002). SBP (Hedges g =−0.18, 95% CI −0.36 to −0.001; 95% PI −0.43 to 0.07; P =.0497) showed a small statistically significant reduction, although the 95% PI crossed the null. No significant effects were observed for diastolic blood pressure (DBP) (Hedges g =−0.11, 95% CI −0.86 to 0.63; 95% PI −2.09 to 1.75; P =.59), high-density lipoprotein cholesterol (HDL) (Hedges g =0.05; 95% CI −0.21 to 0.31; 95% PI −0.54 to 0.57; P =.65), low-density lipoprotein cholesterol (LDL) (Hedges g =−0.26, 95% CI −0.64 to 0.13; 95% PI −1.18 to 0.69; P =.15), total cholesterol (TC) (Hedges g =−0.96, 95% CI −3.79 to 1.88; 95% PI −5.71 to 3.86; P =.37), triglycerides (Hedges g =−0.20, 95% CI −0.70 to 0.31; 95% PI −1.41 to 0.99; P =.38), heart rate (HR) (Hedges g =−0.14, 95% CI −1.74 to 1.46; 95% PI −4.23 to 5.38; P =.47), or glucose (Hedges g =−0.17, 95% CI −0.37 to 0.02; 95% PI −0.42 to 0.07; P =.07) following AVG. No significant BMI subgroup differences were observed by gender, intervention type, or nutritional status. Conclusions This review extends previous evidence by providing an updated RCT-only evaluation of a broader pediatric population and a wider range of cardiometabolic outcomes. AVG were associated with small reductions in BMI and systolic blood pressure (SBP), although evidence for other cardiometabolic outcomes remains uncertain. By clarifying both potential benefits and remaining evidence gaps, this review provides a broader basis for future research and intervention development. AVG may serve as an engaging adjunct to support physical activity participation among children and adolescents.
EUVIMED